New River Pharmaceuticals Inc. ("NRPH") is a specialty
pharmaceutical company developing novel pharmaceuticals that
are generational improvements of widely-prescribed drugs in
large and growing markets. We are developing new molecular
entities that are derivatives of public domain actives using
our proprietary Carrierwave technology.
Our lead product candidates in clinical development are an
amphetamine derivative (NDA filed) and an opioid derivative
that we believe will provide improved alternatives to currently
marketed drugs. In preclinical development, we are researching
a drug for the treatment of chronic pain, which we believe
could reduce the development of opioid tolerance, and a drug
for the treatment of primary hypothyroidism.